A plain language summary of the results from the MAGNITUDE study assessing how effective and how safe niraparib and abiraterone acetate with prednisone is in patients with metastatic castration-resistant prostate cancer. [PDF]
Chi KN +19 more
europepmc +1 more source
Erratum to "Abiraterone Acetate Attenuates SARS-CoV-2 Replication by Interfering with the Structural Nucleocapsid Protein" [Biomol Ther 30(5), 427-434 (2022)]. [PDF]
Kim J +12 more
europepmc +1 more source
Meta-analysis to evaluate the comparative effectiveness of enzalutamide and abiraterone acetate for first-line treatment of metastatic castration-resistant prostate cancer in real-world settings. [PDF]
Aprikian A +9 more
europepmc +1 more source
Long-Term Pharmacokinetic Follow-Up of Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer. [PDF]
Chamorey E +14 more
europepmc +1 more source
Enzalutamide Prolonged the Duration of Drug Use in Comparison to Abiraterone Acetate and Cabazitaxel after Upfront Docetaxel: A Large Japanese Database Study. [PDF]
Yamaguchi K +8 more
europepmc +1 more source
Formulating abiraterone acetate-HPMCAS-based amorphous solid dispersions: insights into in vitro and biorelevant dissolution assessments and pharmacokinetic evaluations. [PDF]
Choudhari M +4 more
europepmc +1 more source
Prediction of PSA Response after Dexamethasone Switch during Abiraterone Acetate + Prednisolone Treatment of Metastatic Castration-Resistant Prostate Cancer Patients. [PDF]
Fekete B +7 more
europepmc +1 more source
Real-world overall survival with abiraterone acetate versus enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer. [PDF]
George DJ +10 more
europepmc +1 more source
Concomitant antihypertensive medication and outcome of patients with metastatic castration-resistant prostate cancer receiving enzalutamide or abiraterone acetate. [PDF]
Fiala O +11 more
europepmc +1 more source
Enzalutamide versus abiraterone acetate in the development of new-onset or worsening type 2 diabetes mellitus in patients with metastatic castration-resistant prostate cancer: EVADE study. [PDF]
Bahl A +8 more
europepmc +1 more source

